Bristol Myers Squibb has presented encouraging results from the TRANSCEND clinical trials at ICML 2023, demonstrating the efficacy and safety of Breyanzi (lisocabtagene maraleucel) relapsed/refractory follicular lymphoma and mantle cell lymphoma patients.
In the TRANSCEND FL trial, which included patients with relapsed or refractory FL, Breyanzi showcased remarkable response rates. Among the patients treated with Breyanzi in the third-line plus setting, 97% achieved a response, with 94% achieving a complete response. After 16.6 months, the median duration of response was not reached. The median progression-free survival (PFS) was not reached at 17.5 months, with 80.7% of patients achieving a 12-month PFS. Breyanzi demonstrated a manageable safety profile, with manageable cytokine release syndrome and neurologic events.
Similarly, in the TRANSCEND NHL 001 trial, Breyanzi exhibited promising results in patients with relapsed or refractory MCL. After a follow-up of 16.2 months, the overall response rate (ORR) among the evaluated patients was 86.5%, with 74.3% achieving a complete response. The safety profile of Breyanzi remained favourable, with no new safety concerns. The occurrence of severe cytokine release syndrome and neurologic events was minimal.
The TRANSCEND FL and TRANSCEND NHL 001 studies underscore the potential of Breyanzi as a best-in-class and best-in-disease CD19-directed CAR T cell therapy for lymphomas.